High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity.
Toxicogenomics, based on the temporal effects of drugs on gene expression, is able to predict toxic effects earlier than traditional technologies by analyzing changes in genomic biomarkers that could precede subsequent protein translation and initiation of histological organ damage. In the present study our objective was to extend in vivo toxicogenomic screening from analyzing one or a few tissues to multiple organs, including heart, kidney, brain, liver and spleen. Nanocapillary quantitative real-time PCR (QRT-PCR) was used in the study, due to its higher throughput, sensitivity and reproducibility, and larger dynamic range compared to DNA microarray technologies. Based on previous data, 56 gene markers were selected coding for proteins with different functions, such as proteins for acute phase response, inflammation, oxidative stress, metabolic processes, heat-shock response, cell cycle/apoptosis regulation and enzymes which are involved in detoxification. Some of the marker genes are specific to certain organs, and some of them are general indicators of toxicity in multiple organs. Utility of the nanocapillary QRT-PCR platform was demonstrated by screening different references, as well as discovery of drug-like compounds for their gene expression profiles in different organs of treated mice in an acute experiment. For each compound, 896 QRT-PCR were done: four organs were used from each of the treated four animals to monitor the relative expression of 56 genes. Based on expression data of the discovery gene set of toxicology biomarkers the cardio- and nephrotoxicity of doxorubicin and sulfasalazin, the hepato- and nephrotoxicity of rotenone, dihydrocoumarin and aniline, and the liver toxicity of 2,4-diaminotoluene could be confirmed. The acute heart and kidney toxicity of the active metabolite SN-38 from its less toxic prodrug, irinotecan could be differentiated, and two novel gene markers for hormone replacement therapy were identified, namely fabp4 and pparg, which were down-regulated by estradiol treatment.
Avicor Ltd., Közép fasor 52, Szeged H-6726, Hungary; E-Mail:  gabriella@avicorbiotech.com.
Gabriella
G
Fabian
Nora
N
Farago
Liliana Z
LZ
Feher
Lajos I
LI
Nagy
Sandor
S
Kulin
Klara
K
Kitajka
Tamas
T
Bito
Vilmos
V
Tubak
Robert L
RL
Katona
Laszlo
L
Tiszlavicz
Laszlo G
LG
Puskas
D000814:Aniline Compounds / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology; D003374:Coumarins / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000187:drug effects; D000077146:Irinotecan; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008807:Mice, Inbred BALB C; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D010655:Phenylenediamines / Q000494:pharmacology; D060888:Real-Time Polymerase Chain Reaction / Q000379:methods; D015203:Reproducibility of Results; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012402:Rotenone / Q000494:pharmacology; D012460:Sulfasalazine / Q000494:pharmacology; D043922:Toxicogenetics / Q000379:methods*; D059467:Transcriptome / Q000187:drug effects*; D015262:Xenobiotics / Q000494:pharmacology*
D000814:Aniline Compounds; D000970:Antineoplastic Agents; D003374:Coumarins; D010655:Phenylenediamines; D015262:Xenobiotics; D012402:Rotenone; D012460:Sulfasalazine; C034805:3,4-dihydro-3,4-dibromo-6-bromomethylcoumarin; D000077146:Irinotecan; D004317:Doxorubicin; C010914:2,4-diaminotoluene; C023650:aniline; D002166:Camptothecin